<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01768585</url>
  </required_header>
  <id_info>
    <org_study_id>HomRate04_2012</org_study_id>
    <nct_id>NCT01768585</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease</brief_title>
  <official_title>A Randomised, Placebo Controlled, Double Blind, Cross-over, Single Center Clinical Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Saarland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Saarland University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Saarland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates whether chronic heart rate reduction with ivabradine (Procoralan®,
      Servier, France) affects aortic compliance and endothelial function in patients with chronic
      stable coronary artery disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Experimental and clinical data suggest that sustained elevation of heart rate contributes to
      the pathogenesis of vascular disease (1, 2). In animal studies accelerated heart rate is
      associated with signalling events leading to vascular oxidative stress, endothelial
      dysfunction and acceleration of atherogenesis (3). The underlying mechanisms are only
      partially understood and appear to correlate with mechanic properties such as reduction of
      vascular compliance. Heart rate reduction by I(f)-channel inhibition with ivabradine
      (Procoralan®, Servier, France) attenuates oxidative stress, improves endothelial function and
      reduces the formation of atherosclerotic plaques in mice models of lipid-induced
      atherosclerosis (1, 4).

      Aortic stiffness is a consequence of arterial aging and vascular risk factors and
      determinates cardiovascular mortality (5). Heart rate depending repetitive pulsations appear
      to induce fatigue and fracture of elastin lamellae of central arteries. As a result the
      vessel stiffens and pulse wave reflections return earlier to the heart. In consequence aortic
      pressure rises and pulsations of flow extend further into smaller vessels of organs (notably
      the brain and kidney). Stiffening leads to increased left ventricular (LV) load with
      hypertrophy, decreased capacity for myocardial perfusion, and increased hemodynamic stresses
      on small arterial vessels.

      Several experimental investigations revealed an interaction between heart rate and vascular
      compliance demonstrating a positive association between increased heart rate and arterial
      stiffness (6). Recent experimental data suggest that heart rate reduction by ivabradine
      (Procoralan®, Servier, France) significantly improves aortic distensibility in cholesterol
      fed ApoE -/- mice measured by MRI technique (7). While a benefit of pharmacological heart
      rate reduction on vascular outcomes was observed in animal studies, prospective clinical data
      are limited and evidence determining whether chronic modulation of heart rate can improve
      vascular function and compliance in patients with chronic stable coronary artery disease is
      needed.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aortic distensibility (MRI), pulse wave velocity (SphygmoCor®), flow-mediated dilatation (A. brachialis)</measure>
    <time_frame>Decembre 2014</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarkers (inflammation, oxidative stress)</measure>
    <time_frame>Decembre 2014</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Arteriosclerosis</condition>
  <arm_group>
    <arm_group_label>Ivabradine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Ivabradine bid administration of 7.5mg ivabradine Other Name: Procoralan, I(f)-inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo bid placebo Other Name: Placebo control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivabradine</intervention_name>
    <description>Please see description of Intervention Arm</description>
    <arm_group_label>Ivabradine</arm_group_label>
    <other_name>Procoralan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years old

          -  Resting heart rate ≥ 70 bpm

          -  Sinus rhythm

          -  Chronic stable coronary artery disease (CAD)

          -  Coronary artery disease proven by coronary angiography

          -  Written informed consent to participate in the study

        Exclusion Criteria:

          -  Acute coronary syndrome

          -  CAD treated best by surgical coronary bypass

          -  Stroke/TIA

          -  Resting heart rate &lt; 70 bpm

          -  Indwelling pacemaker or AICD

          -  Severe valvular heart disease

          -  Any other rhythm than sinus

          -  Sick-Sinus-Syndrome, SA nodal block, &gt;2nd degree atrio-ventricular block

          -  Untreated arterial hypertension

          -  Arterial hypotension (&lt;90/50mmHg)

          -  Severe hepatic failure

          -  Heart failure (NYHA class III - IV)

          -  Patient already treated with study drug

          -  Symptomatic PAD

          -  Known diabetes mellitus

          -  Pre-menopausal women

          -  Hypersensitivity against ivabradine or adjuvants

          -  Coexisting drug treatment with Cytochrom P450 3A4-inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrich Laufs</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saarland University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Florian Custodis, MD</last_name>
    <phone>0049-6841-1623000</phone>
    <email>Florian.Custodis@uks.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angelika Knoll</last_name>
    <phone>0049-6841-23412</phone>
    <email>Angelika.Knoll@uks.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital, Saarland</name>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Custodis, MD</last_name>
      <phone>0049-6841-1623000</phone>
      <email>Florian.Custodis@uks.eu</email>
    </contact>
    <contact_backup>
      <last_name>Angelika Knoll</last_name>
      <phone>0049-6841-1623412</phone>
      <email>Angelika.Knoll@uks.eu</email>
    </contact_backup>
    <investigator>
      <last_name>Ulrich Laufs, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florian Custodis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Custodis F, Baumhäkel M, Schlimmer N, List F, Gensch C, Böhm M, Laufs U. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2008 May 6;117(18):2377-87. doi: 10.1161/CIRCULATIONAHA.107.746537. Epub 2008 Apr 28.</citation>
    <PMID>18443241</PMID>
  </reference>
  <reference>
    <citation>Beere PA, Glagov S, Zarins CK. Retarding effect of lowered heart rate on coronary atherosclerosis. Science. 1984 Oct 12;226(4671):180-2.</citation>
    <PMID>6484569</PMID>
  </reference>
  <reference>
    <citation>Custodis F, Schirmer SH, Baumhäkel M, Heusch G, Böhm M, Laufs U. Vascular pathophysiology in response to increased heart rate. J Am Coll Cardiol. 2010 Dec 7;56(24):1973-83. doi: 10.1016/j.jacc.2010.09.014. Review.</citation>
    <PMID>21126638</PMID>
  </reference>
  <reference>
    <citation>Noels H, Weber C. Fractalkine as an important target of aspirin in the prevention of atherogenesis : Editorial to: &quot;Aspirin inhibits fractalkine expression in atherosclerotic plaques and reduces atherosclerosis in ApoE gene knockout mice&quot; by H. Liu et al. Cardiovasc Drugs Ther. 2010 Feb;24(1):1-3. doi: 10.1007/s10557-009-6213-4.</citation>
    <PMID>20033269</PMID>
  </reference>
  <reference>
    <citation>Cavalcante JL, Lima JA, Redheuil A, Al-Mallah MH. Aortic stiffness: current understanding and future directions. J Am Coll Cardiol. 2011 Apr 5;57(14):1511-22. doi: 10.1016/j.jacc.2010.12.017. Review.</citation>
    <PMID>21453829</PMID>
  </reference>
  <reference>
    <citation>Mangoni AA, Mircoli L, Giannattasio C, Ferrari AU, Mancia G. Heart rate-dependence of arterial distensibility in vivo. J Hypertens. 1996 Jul;14(7):897-901.</citation>
    <PMID>8818929</PMID>
  </reference>
  <reference>
    <citation>Custodis F, Fries P, Müller A, Stamm C, Grube M, Kroemer HK, Böhm M, Laufs U. Heart rate reduction by ivabradine improves aortic compliance in apolipoprotein E-deficient mice. J Vasc Res. 2012;49(5):432-40. doi: 10.1159/000339547. Epub 2012 Jul 3.</citation>
    <PMID>22759927</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2013</study_first_submitted>
  <study_first_submitted_qc>January 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2013</study_first_posted>
  <last_update_submitted>January 14, 2013</last_update_submitted>
  <last_update_submitted_qc>January 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

